Table 54Clinical Remission or Response in the Maintenance Phase

ComparatorSingh et al.Hazelwood et al.Miligkos et al.a
Vedolizumab
(RR 95% CrI)		Vedolizumab
(OR 95% CrI)		Vedolizumab
(OR 95% CI)		Vedolizumab
(OR 95% CI)
Clinical RemissionClinical Response
PLA2.20 (0.37 to 13.54)2.2 (1.3 to 3.7)NRNR
IFX0.67 (0.06 to 5.64)0.77 (0.39 to 1.5)1.61 (0.80 to 3.22)1.95 (1.03 to 3.70)
ADA0.43 (0.05 to 3.36)0.42 (0.22 to 0.85)2.22 (1.20 to 4.09)2.23 (1.26 to 3.93)
CRT0.97 (0.08 to 12.54)1.1 (0.57 to 2.1)1.02 (0.56 to 1.87)1.60 (0.90 to 2.82)
UTKNRbNANRNR
NAT0.52 (0.04 to 6.62)NA1.98 (1.03 to 3.81)2.15 (1.15 to 4.00)
AZA/6-MPNA1.3 (0.65 to 2.3)NANA
MTXNA0.91 (0.39 to 2.3)NANA
IFX + AZANA0.42 (0.17 to 0.92)NANA
IFC + MTXNA0.85 (0.29 to 2.5)NANA

6-MP = 6-mercaptopurine; ADA = adalimumab; AZA = azathioprine; CI = confidence interval; CrI = credible interval; CRT = certolizumab; IFX = infliximab; MTX = methotrexate; NA = not available; NAT = natalizumab; NMA = network meta-analysis; NR = not reported; OR = odds ratio; PLA = placebo; RR = relative risk; UTK = ustekinumab.

a

ORs reported in the NMA conducted by Miligkos et al. are presented as the OR of the comparator versus vedolizumab.

b

Relative risk was reported only for ustekinumab compared with vedolizumab (RR 0.87; 95% CrI, 0.07 to 11.36).

Source: Singh et al.,51 Hazelwood et al.,52 Miligkos et al.61

From: APPENDIX 7, SUMMARY OF PUBLISHED INDIRECT COMPARISONS

Cover of Entyvio (Vedolizumab)
Entyvio (Vedolizumab) [Internet].
Copyright © CADTH 2016.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.